Related Experiment Video
Updated: Jun 22, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
248
Quality Assurance Model for Breast Cancer Prognostication Using the Modified Magee Equations
Ian Lagerstrom1, Daniel Neelon1, Nena Wendzel2
1From the Department of Pathology, Walter Reed National Military Medical Center, Bethesda, Maryland (Lagerstrom, Neelon, Wells).
Archives of Pathology & Laboratory Medicine
|July 2, 2024
Summary
The Magee score (MS) acts as a quality check for the Oncotype DX recurrence score (RS) in breast cancer. This method identified significant discrepancies in 16.1% of cases, improving treatment decisions.
Area of Science:
- Oncology
- Pathology
- Genomics
Background:
- The Oncotype DX recurrence score (RS) is crucial for early-stage, hormone receptor-positive breast cancer, guiding prognosis and chemotherapy benefit.
- Quality assurance for RS lacks the scrutiny applied to other tests like HER2 immunohistochemistry.
Purpose of the Study:
- To implement the Magee score (MS) using modified Magee equations as a quality control measure for the Oncotype DX recurrence score (RS).
Main Methods:
- Calculated MS using histopathologic and immunohistochemical criteria.
- Identified significant discordances where RS and MS differed by ≥10 points or risk categories.
- Presented discordant cases at multidisciplinary tumor boards for clinical significance assessment.
Main Results:
- Significant discrepancies between RS and MS were found in 25 of 155 cases (16.1%).
- Of the discordant cases, 3 (12%) indicated issues with either the RS or histopathologic interpretation.
- Concordant cases showed no identified problems with RS or interpretation.
Conclusions:
- Utilizing MS as a quality check for RS enhances the accuracy of treatment decisions for breast cancer patients.
- Pathologists are vital in ensuring the quality of molecular prognostic scores through histopathologic models, improving risk stratification and clinical outcomes.
